Neutron studies of HIV inhibitors reveal new areas for improvement in drug design to enhance performance, combat resista
Tuesday, August 13, 2013 - 08:00
in Health & Medicine
The first study of interactions between a common clinical inhibitor and the HIV-1 protease enzyme has been carried out by an international team with members from the US, Britain and France using neutrons at the Institut Laue-Langevin in Grenoble, France. It provides medical science with the first true picture of how an antiviral drug used to block virus replication actually works, and critically how its performance could be improved.